tm logo
Live/Registered
REGISTERED

on 14 Nov 2017

Last Applicant/ Owned by

Meditrina, Babraham Research Campus

Cambridge

GB

CB223AT

Serial Number

87052324 filed on 27th May 2016

Registration Number

5332632 registered on 14th Nov 2017

in the Principal Register

Correspondent Address

MARK HARRISON

VENABLE LLP

P.O. BOX 34385

WASHINGTON, DC 20043

Filing Basis

1. intent to use

Disclaimer

NO DATA

Logo Mark Trademark Information

Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments The mark consists of a circle which has a u-shaped portion missing from its centRead More

Classification Information


Class [001]
Chemical Products


Chemicals for use in industry and science; chemicals test kits for in vitro testing for laboratory research purposes; biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for scientific and laboratory research use; biochemical, namely, monoclonal antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products

Class [005]
Pharmaceutical Products


Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; monoclonal antibody therapeutic preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; antibodies and antibody fragments being diagnostic reagents for medical and veterinary diagnostics; antibodies and antibody fragments for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases for use in the manufacture of therapeutic products

Class [031]
Natural Agricultural Products


Live animals; live mice

Class [040]
Treatment & Processing of Materials Services


Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments

Class [042]
Computer & Software Services & Scientific Services


Scientific and technological services, namely, scientific research, analysis and testing, and research and design in the field of therapeutic pharmaceuticals; scientific laboratory services; laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, therapeutic products

Mark Details


Serial Number

No 87052324

Mark Type

No Service Mark

Attorney Docket Number

No 60895-403227

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Design Code(s)

26.01.03 -

Incomplete circles (more than semi-circles)

Description of Design Search

The mark consists of a circle which has a u-shaped portion missing from its central top.

Legal History


Show more

Status DateAction Taken
14th Nov 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
14th Nov 2017REGISTERED-PRINCIPAL REGISTER
29th Aug 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29th Aug 2017PUBLISHED FOR OPPOSITION
09th Aug 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26th Jul 2017APPROVED FOR PUB - PRINCIPAL REGISTER
19th Jul 2017TEAS/EMAIL CORRESPONDENCE ENTERED
19th Jul 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
18th Jul 2017ASSIGNED TO LIE
09th Jun 2017TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED